I

Iovance Biotherapeutics

TIL-based T-cell therapies for solid tumors

IT Support Analyst 2

Full-Time
No salary listed
Junior
Bachelor's, Associate's
Philadelphia, PA, USA
In PersonFully on-site at the manufacturing facility; travel of up to 5–10% may be required.
IT OperationsIT Service Desk & End User Support

About the job

Requirements
  • At least 2 years of experience providing IT helpdesk support in a fast-paced business environment.
  • Ability to lift or move computer equipment weighing up to 50 pounds.
  • Strong proficiency with Microsoft 365, including Outlook, Word, Excel, PowerPoint, and Teams.
  • Strong hardware troubleshooting and repair skills with desktops, workstations, laptops, printers, and mobile devices.
  • Experience supporting executives' IT needs.
  • Broad IT experience with a strong understanding of networks, servers, and telecommunications.
  • Strong customer service skills.
  • Ability to provide consistent customer support to staff across varied personalities and management levels.
  • Strong written and verbal communication skills.
  • Ability to mentor or provide best practices to other team members.
  • Familiarity with Information Technology Infrastructure Library processes and framework.
  • Familiarity with 21 CFR Part 11 and standard GxP best practices.
  • Ability to work in a flexible, team-oriented environment.
  • Ability to remain stationary while standing or sitting for prolonged periods.
  • Ability to move about an office and exert up to 10 pounds of force occasionally, or negligible force frequently or constantly, to move objects.
  • Visual acuity for preparing and analyzing data and figures, viewing computer screens, and extensive reading.
  • Ability to perform repetitive wrist, hand, and finger motions.
  • Ability to communicate with others to exchange information.
  • Clear and conceptual thinking, sound judgment, troubleshooting, problem-solving, analysis, discretion, stress management, prioritization, and deadline management.
Responsibilities
  • Provide on-site IT support to Philadelphia staff and remote support to other United States offices.
  • Support laptops, desktops, hardware, printers, scanners, and other computer peripherals.
  • Calibrate and troubleshoot Zebra printers.
  • Support audio/video conference-room equipment, telephone systems, meeting software, messaging and collaboration tools, and Zoom Rooms.
  • Support Microsoft 365, including SharePoint, permissions, and access management.
  • Support network devices and infrastructure, including routers, switches, firewalls, racks, and cabling.
  • Manage and troubleshoot mobile devices, including Android and iOS devices.
  • Manage the ticketing queue for assigned tickets.
  • Support IT needs in laboratories and support executive IT needs.
  • Produce and maintain documentation and asset-management data for hardware and software.
  • Conduct new-hire orientation and basic IT training, and ensure timely completion of offboarding.
  • Provide IT support for town halls, critical meetings, audits, and all-hands events.
  • Install and support common IT applications.
  • Manage computer imaging and patching operations to maintain compliance with company policies.
  • Produce reports on IT operations, ticket metrics, and asset inventory.
  • Liaise with third-party vendors for procurement and timely delivery of IT equipment.
  • Translate technical concepts into clear, understandable language for end users.
  • Provide status and completion updates to supervisors and end users through email, chat, or in-person communication.
  • Collaborate with vendors to streamline support processes and improve operational efficiency.
  • Adhere to company values, policies, procedures, and business ethics.
  • Perform miscellaneous duties as assigned.
Desired Qualifications
  • Experience with Microsoft 365, SharePoint, and Entra ID (Azure Active Directory).
  • Experience with Lenovo and Dell laptops running Windows 11.
  • Experience with Okta single sign-on and multi-factor authentication.
  • Experience with Microsoft Intune for device enrollment, policy configuration, compliance management, and application deployment across Windows, iOS, and Android platforms.
  • Familiarity with Intune Autopilot for zero-touch device provisioning and automated Windows deployment.
  • Ability to troubleshoot Intune-managed device issues, including enrollment failures, policy conflicts, and conditional-access problems.
  • Understanding of TCP/IP, HTTP/HTTPS, FTP, DNS, and DHCP protocols.
  • CompTIA A+ or another relevant certification.
  • An Associate or Bachelor's degree in Computer Science, Information Systems, or a related field.
  • Experience setting up systems, users, roles, access levels, and user onboarding training.
  • Experience providing tier-two triage for application incidents reported through the help desk.
  • Experience analyzing systems, applications, and databases and coordinating implementation and maintenance plans, including troubleshooting issues.
  • Experience supporting office systems for tier-two end-user and conference/event support.
  • Experience assisting with new-hire orientation.
  • Ability to work a flexible day and hour schedule as required.

About the company

I

Iovance Biotherapeutics

View

Iovance Biotherapeutics develops cancer immunotherapies using Tumor Infiltrating Lymphocytes (TIL). It harvests T cells from a patient’s tumor, expands them in the lab, and infuses them back into the patient to attack solid tumors. The therapies are designed as single-treatment treatments without the need for ongoing maintenance. The company differentiates itself by focusing on TIL-based adoptive cell therapy with broad antigen targeting and dedicated cell therapy manufacturing capabilities, including the Iovance Cell Therapy Center (iCTC) to scale production. Its goal is to develop, manufacture, and commercialize proprietary TIL therapies and expand access to cell-based cancer treatments through partnerships and scaled production.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Carlos, California

Founded

2007

Get referred to Iovance Biotherapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 29, 2026 revenue guidance rose to $410 million–$420 million for 2026.
  • October 1, 2026 CMO Noah Berkowitz strengthens late-stage development and regulatory execution.
  • Fast Track programs in lung, sarcoma, and endometrial cancer expand the addressable market.

What critics are saying

  • Amtagvi remains the only real commercial engine; a slowdown breaks the whole thesis.
  • 2025 securities and derivative litigation still hangs over management through 2026.
  • Manufacturing complexity and center adoption bottlenecks can delay volume growth into 2027.

What makes Iovance Biotherapeutics unique

  • Amtagvi became FDA-approved in 2024, validating Iovance’s autologous TIL platform.
  • Philadelphia iCTC centralizes manufacturing, giving Iovance control over supply and margins.
  • Iovance pairs one-time TIL treatment with expanding authorized centers across multiple countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

3%
Healthcare Industry Today
Oct 6th, 2026
AVBCC recognizes Iovance Biotherapeutics' Dr. Fred Vogt with inaugural Global Cancer Research & Innovation Award.

AVBCC recognizes Iovance Biotherapeutics' Dr. Fred Vogt with inaugural Global Cancer Research & Innovation Award. AVBCC has presented its Global Cancer Research & Innovation Award to Fred Vogt, PhD, JD, Interim CEO, President, and General Counsel, Iovance Biotherapeutics. Dr. Vogt's extraordinary blend of scientific leadership, strategic vision, and unwavering commitment to advancing breakthrough therapies embodies the spirit of innovation and impact this award honors." - Burt Zweigenhaft, PhD, DLitt NEW YORK, NY, UNITED STATES, October 6, 2026 / EINPresswire.com / - The Association for Value-Based Cancer Care (AVBCC) is pleased to announce Fred Vogt, PhD, JD, Interim CEO, President, and General Counsel, Iovance Biotherapeutics, as the recipient of its inaugural Global Cancer Research & Innovation Award. Presented to Dr. Vogt today at AVBCC's 2nd Annual Global Cancer Research & Innovation Symposium (GCRIS), this award recognizes his visionary leadership and contributions to advancing innovation in oncology. Now in its second year, AVBCC's GCRIS serves as a catalyst for advancing the future of cancer care by convening leading experts to explore breakthrough science, emerging therapies, and highlight innovations transforming cancer treatment worldwide. "The Global Cancer Research & Innovation Award is a reflection of AVBCC's commitment to celebrating the individuals and organizations driving progress across the oncology innovation ecosystem," says Burt Zweigenhaft, PhD, DLitt, Executive Director and Founder, AVBCC. "Dr. Vogt's extraordinary blend of scientific leadership, strategic vision, and unwavering commitment to advancing breakthrough therapies embodies the spirit of innovation and impact that this award was created to honor." "I am deeply honored to receive the inaugural Global Cancer Research & Innovation Award from the Association for Value-Based Cancer Care," says Dr. Vogt. "This recognition reflects the dedication of the entire Iovance team to make the promise of TIL therapy a reality for patients with advanced melanoma. The approval and launch of Amtagvi (R) underscored the potential for cell therapy to fundamentally change the treatment landscape for solid tumor cancers, and I'm grateful to the Association for championing innovation that ultimately benefits the patients who need it most." In 2024, Dr. Vogt led Iovance through one of the most significant milestones in modern oncology with the FDA approval and commercial launch of Amtagvi (R)(lifileucel), the first cell therapy ever approved for a solid tumor. This achievement opened an entirely new category of cancer treatment for patients with advanced melanoma and underscores the broader scientific and organizational progress he has championed. At Iovance's helm, Dr. Vogt has overseen the development of its end-to-end manufacturing infrastructure and commercial transformation including the acquisition and integration of Proleukin (R)- a decision that strengthened Iovance's ability to support the TIL therapy regimen. Additionally, he has spent more than 25 years advancing breakthrough cancer therapies across the industry, contributing to the approvals of Hycamtin (R), Votrient (R), Tafinlar (R), Mekinist (R), and Arzerra (R). With a rare dual background as both scientist and business leader, Dr. Vogt embodies the entrepreneurship, integrity, and patient centered commitment recognized by this award. About the Association for Value-Based Cancer Care (AVBCC) AVBCC is a 501(c)(6) educational organization dedicated to fostering the exchange of knowledge among stakeholders across the cancer care ecosystem who are responsible for ensuring that optimal care and access are delivered to all patients with cancer. Its goal is to inform, educate, and foster exchange of current and future state information between all stakeholders: Oncologists and Hematologists, Nurses, Oncology Nurse Navigators, Pathologists and Geneticists, Pharmacists, Practice Administrators, Practice Managers, Patient Advocacy Organizations, Managed Care Organizations, Insurance Companies, Third-Party Payers, Integrated Health Delivery Systems, Cancer Centers of Excellence, Medical Directors, Pharmacy Directors, Pharmaceutical and Biotech Manufacturers, Personalized Medicine Providers, Researchers, and, of course, cancer patients. Visit AVBCC.org to learn more about its organization and offerings. About Iovance Biotherapeutics Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi (R)(lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com. Amtagvi (R) and its accompanying design marks, Proleukin (R), Iovance (R), and IovanceCares(TM) are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Information on Iovance's broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Healthcare Industry Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Yahoo Finance
Oct 4th, 2026
Iovance soars 256% on upgraded 2026 revenue guidance of $410M–$420M

Iovance Biotherapeutics became the top-performing mid-cap stock in the US market in Q3, with shares soaring 256%. The rally was driven by raised 2026 revenue guidance of $410 million to $420 million, representing 56% to 60% growth from 2025's $263 million. The company's optimism stems from strong demand for cancer treatments Amtagvi and Proleukin. In Q2, Iovance reported net revenues of $99 million, up 66% year-on-year, with $91 million from Amtagvi and $9 million from Proleukin. Amtagvi is the first FDA-approved individualised T-cell therapy for solid tumour cancer, specifically treating unresectable or metastatic melanoma. It has received regulatory approval in the US, Canada, and Australia. Analysts responded positively, with HC Wainwright raising its price target to $20 from $9 and Goldman Sachs assigning a $15 target.

Yahoo Finance
Oct 1st, 2026
Iovance appoints Noah Berkowitz as chief medical officer to advance TIL therapies

Iovance Biotherapeutics has appointed Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, effective 30 September 2026. The Philadelphia-based biotechnology company develops tumour infiltrating lymphocyte therapies for cancer patients. Berkowitz previously served as Chief Medical Officer at Arvinas Pharmaceuticals, where he led the clinical strategy resulting in the first FDA approval of a targeted protein degradation therapy. Before that, he held senior positions at Bristol Myers Squibb, overseeing development teams that achieved regulatory approvals for CAR T cell therapies Abecma and Breyanzi. In connection with the appointment, Iovance granted Berkowitz inducement stock options and restricted stock units covering up to 450,000 shares at an exercise price of $14.82. The awards vest over three years.

Asianet News
Sep 29th, 2026
IOVA stock hits over 2-year highs - why Iovance raised its FY2026 revenue outlook.

IOVA stock hits over 2-year highs - why Iovance raised its FY2026 revenue outlook. Published: Sep 29 2026, 08:10 PM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us Iovance raised its 2026 revenue forecast due to strong U.S. demand for Amtagvi and Proleukin cancer therapies. * Iovance expects FY 2026 revenue of $410 million to $420 million, up from $350 million to $370 million. * The company is expected to report its Q3 results in November. * Lifileucel is being developed beyond its current melanoma use, including programs in lung and endometrial cancers. Shares of Iovance Biotherapeutics (IOVA) surged to their highest levels in more than two years on Tuesday, after the biotech firm raised its full-year revenue outlook, citing stronger U.S. demand for its cancer treatments. At the time of writing, IOVA stock was up more than 25% and heading for its fourth monthly gain in five months. Why did Iovance raise its guidance? Iovance said it expects full-year 2026 revenue of $410 million to $420 million, up from its previous $350 million to $370 million forecast. The new midpoint is $55 million higher and implies nearly 60% annual growth, it said. The increased outlook follows a record second quarter. Iovance reported $99.3 million in second-quarter (Q2) product revenue, including $89.5 million from Amtagvi (lifileucel) and $9.8 million from Proleukin. Amtagvi is a tumor-infiltrating lymphocyte therapy approved for certain patients with advanced melanoma. Proleukin is used to treat adults with kidney cancer as well as metastatic melanoma. "Increasing patient demand and our current manufacturing schedule provide strong visibility into our third and fourth quarter revenues," said Frederick Vogt, Interim President and CEO. Goldman Sachs recently resumed coverage of Iovance with a 'Buy' rating and $15 price target, saying operational and logistical challenges surrounding the Amtagvi launch are beginning to ease and should support better gross margins. Pipeline looks beyond melanoma. Iovance is trying to expand lifileucel beyond its current melanoma indication. The company is running the Tilvance-301 Phase 3 study of lifileucel plus Merck's Keytruda as a first-line treatment for advanced melanoma. Its pipeline also includes registrational programs evaluating lifileucel in non-small cell lung cancer and endometrial cancer. Iovance ended Q2 with about $243 million in cash, cash equivalents and investments. The company said it has been working to reduce expenses and improve manufacturing efficiency. The company expects to report its third-quarter (Q3) results in early November. Retail sees upside in lung cancer treatment. Retail sentiment surrounding IOVA on Stocktwits remained 'bullish' over the past 24 hours, amid 'high' message volumes. One user highlighted the company's potential opportunity in lung cancer treatment. View this Stocktwits post Another user said positive lung cancer data will take the stock to $20. It is currently trading at $13.3. View this Stocktwits post The stock has surged around 425% so far this year. Also read: QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington's Disease Data - Here's What Investors Need To Know For updates and corrections, email newsroom[at]stocktwits[dot]com< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

Yahoo Finance
Sep 29th, 2026
Iovance shares jump 14% as $415M revenue outlook tops $403M analyst estimate

Iovance Biotherapeutics shares surged over 14% in premarket trading Tuesday after the biotechnology company raised its full-year 2026 revenue outlook to between $410 million and $420 million, exceeding the consensus analyst estimate of $402.8 million. The revised guidance represents a $55 million increase at the midpoint from the prior range of $350 million to $370 million, reflecting nearly 60% annual revenue growth. The boost follows record second-quarter product revenue of $99.3 million. Management attributed the stronger outlook to robust domestic adoption of its tumour-infiltrating lymphocyte therapy, Amtagvi, and sustained sales of Proleukin. The company has expanded its authorised treatment centre network to approximately 100 locations and aims to reach at least 110 centres by end-2026. Iovance will report full third-quarter results in early November.